ARCHIVES

Tamoxifen: No Mortality Benefit For Most “High Risk” Women

This article is from The Cancer Letter archive.

Vol. 29 No. 9 | September 29, 2006

Download PDF Visit The Full Archive

Related Articles

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

September 26, 2014

Cooperation Is ACS Theme For ‘90s; Dodd

February 1, 1991

Frelick To Receive ACCC Annual Award Will Leave NCI In July

March 6, 1987

Pittsburgh Cancer Institute Wins SPORE Grant For Lung Cancer, For Three Major Projects.

July 20, 2001

Niederhuber: Clinical Trials System Must Refocus To Emphasize Translational Studies.

July 9, 2010

House Approves Waxman Bill Unanimously; Hatch Introduces His Measure

June 21, 1985